Amicus Therapeutics (NASDAQ:FOLD) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07), Zacks reports. Amicus Therapeutics had a positive return on equity of 12.44% and a negative net margin of 10.62%. The firm had revenue of $149.70 million for the quarter, compared to the consensus estimate of $147.88 million. During the same quarter in the prior year, the firm earned $0.01 EPS. The company's revenue was up 30.1% on a year-over-year basis. Amicus Therapeutics updated its FY 2025 guidance to EPS.

Amicus Therapeutics Price Performance

FOLD traded up $0.12 during trading on Friday, hitting $9.19. 2,603,411 shares of the stock traded hands, compared to its average volume of 2,128,267. Amicus Therapeutics has a twelve month low of $8.78 and a twelve month high of $14.02. The company has a market cap of $2.82 billion, a price-to-earnings ratio of -51.06, a PEG ratio of 1.51 and a beta of 0.61. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The business has a 50 day moving average price of $9.56 and a 200 day moving average price of $10.41.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on FOLD shares. Morgan Stanley restated an "equal weight" rating and set a $12.00 price objective (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday. Needham & Company LLC restated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $21.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Finally, Wells Fargo & Company dropped their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $16.75.

Insider Buying and Selling at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the business's stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at $8,884,273.08. The trade was a 0.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.20% of the company's stock.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.